

Highlights of This Issue 5089

SPECIAL FEATURES

CCR Translations

- 5091 | **CD44: A Cancer Stem Cell–Related Biomarker with Predictive Potential for Radiotherapy**
Michael Baumann and Mechthild Krause
See article p. 5329

CCR New Strategies

- 5094 | **New Strategies in Ovarian Cancer: Uptake and Experience of Women at High Risk of Ovarian Cancer Who Are Considering Risk-Reducing Salpingo-Oophorectomy**
Suzanne M. Miller, Pagona Roussi, Mary B. Daly, and John Scarpato

Molecular Pathways

- 5107 | **Therapeutic Targeting of the DNA Mismatch Repair Pathway**
Sarah A. Martin, Christopher J. Lord, and Alan Ashworth

HUMAN CANCER BIOLOGY

- 5114 | **A Novel Correlation between *LINE-1* Hypomethylation and the Malignancy of Gastrointestinal Stromal Tumors**
Shinichi Igarashi, Hiromu Suzuki, Takeshi Niinuma, Haruo Shimizu, Masanori Nojima, Hiroyuki Iwaki, Takayuki Nobuoka, Toshiro Nishida, Yasuaki Miyazaki, Hiroyuki Takamaru, Eiichiro Yamamoto, Hiroyuki Yamamoto, Takashi Tokino, Tadashi Hasegawa, Koichi Hirata, Kohzoh Imai, Minoru Toyota, and Yasuhisa Shinomura
- 5124 | **Glycogen Synthase Kinase-3 β : A Prognostic Marker and a Potential Therapeutic Target in Human Bladder Cancer**
Sei Naito, Vladimir Bilim, Kaori Yuuki, Andrey Ugol'kov, Teiichi Motoyama, Akira Nagaoka, Tomoyuki Kato, and Yoshihiko Tomita

- 5133 | **Inactivation of the *APC* Gene Is Constant in Adrenocortical Tumors from Patients with Familial Adenomatous Polyposis but Not Frequent in Sporadic Adrenocortical Cancers**
Sébastien Gaujoux, Stéphane Pinson, Anne-Paule Gimenez-Roqueplo, Laurence Amar, Bruno Ragazzon, Pierre Launay, Tchao Meatchi, Rossella Libé, Xavier Bertagna, Anne Audebourg, Jessica Zucman-Rossi, Frédérique Tissier, and Jérôme Bertherat

- 5142 | **von Hippel-Lindau–Dependent Patterns of RNA Polymerase II Hydroxylation in Human Renal Clear Cell Carcinomas**
Ying Yi, Olga Mikhaylova, Aygun Mamedova, Prabhat Bastola, Jacek Biesiada, Enas Alshaikh, Linda Levin, Rachel M. Sheridan, Jarek Meller, and Maria F. Czyzyk-Krzeska

CANCER THERAPY: PRECLINICAL

- 5153 | **Orally Administered Particulate β -Glucan Modulates Tumor-Capturing Dendritic Cells and Improves Antitumor T-Cell Responses in Cancer**
Bing Li, Yihua Cai, Chunjian Qi, Richard Hansen, Chuanlin Ding, Thomas C. Mitchell, and Jun Yan
- 5165 | **Synergistic Killing Effect between Vorinostat and Target of CD146 in Malignant Cells**
Xiaoli Ma, Jia Liu, Jiang Wu, Xiyun Yan, Peng Wu, Yong Liu, Shuang Li, Yuan Tian, Yang Cao, Gang Chen, Li Meng, Gang Xu, Shixuan Wang, Yunping Lu, Ding Ma, and Jianfeng Zhou
- 5177 | **PF-03732010: A Fully Human Monoclonal Antibody against P-Cadherin with Antitumor and Antimetastatic Activity**
Cathy C. Zhang, Zhengming Yan, Qin Zhang, Kyle Kuszpit, Kenneth Zasadny, Ming Qiu, Cory L. Painter, Anthony Wong, Eugenia Kraynov, Maria E. Arango, Pramod P. Mehta, Ian Popoff, Gerald F. Casperson, Gerrit Los, Steve Bender, Kenna Anderes, James G. Christensen, and Todd VanArsdale

5189 **Sorafenib Overcomes TRAIL Resistance of Hepatocellular Carcinoma Cells through the Inhibition of STAT3**
Kuen-Feng Chen, Wei-Tien Tai, Tsung-Hao Liu, Hsiang-Po Huang, Yu-Chin Lin, Chung-Wai Shiau, Pui-Kai Li, Pei-Jer Chen, and Ann-Lii Cheng

5200 **cIAP2 Upregulated by E6 Oncoprotein via Epidermal Growth Factor Receptor/Phosphatidylinositol 3-Kinase/AKT Pathway Confers Resistance to Cisplatin in Human Papillomavirus 16/18-Infected Lung Cancer**
Heng-Hsiung Wu, Jeng-Yuan Wu, Ya-Wen Cheng, Chi-Yi Chen, Ming-Ching Lee, Yih-Gang Goan, and Huei Lee

5244 **Single-Nucleotide Polymorphisms in p53 Pathway and Aggressiveness of Prostate Cancer in a Caucasian Population**
Tong Sun, Gwo-Shu Mary Lee, William K. Oh, Mark Pomerantz, Ming Yang, Wanling Xie, Matthew L. Freedman, and Philip W. Kantoff

5252 **Genetic Risk Profiles Identify Different Molecular Etiologies for Glioma**
Matthias Simon, Fay J. Hosking, Yannick Marie, Konstantinos Gousias, Blandine Boisselier, Catherine Carpentier, Johannes Schramm, Karima Mokhtari, Khe Hoang-Xuan, Ahmed Idbah, Jean-Yves Delattre, Mark Lathrop, Lindsay B. Robertson, Richard S. Houlston, and Marc Sanson

IMAGING, DIAGNOSIS, PROGNOSIS

5211 **Patterns of Expression of DNA Repair Genes and Relapse From Melanoma**
Rosalyn Jewell, Caroline Conway, Angana Mitra, Juliette Randerson-Moor, Samira Lobo, Jérémie Nsengimana, Mark Harland, Maria Marples, Sara Edward, Martin Cook, Barry Powell, Andy Boon, Floor de Kort, Katharine A. Parker, Ian A. Cree, Jennifer H. Barrett, Margaret A. Knowles, D. Timothy Bishop, and Julia Newton-Bishop

5222 **A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor-Positive Breast Cancer**
Torsten O. Nielsen, Joel S. Parker, Samuel Leung, David Voduc, Mark Ebbert, Tammi Vickery, Sherri R. Davies, Jacqueline Snider, Inge J. Stijleman, Jerry Reed, Maggie C.U. Cheang, Elaine R. Mardis, Charles M. Perou, Philip S. Bernard, and Matthew J. Ellis

5233 **M30 Neopeptide Expression in Epithelial Cancer: Quantification of Apoptosis in Circulating Tumor Cells by CellSearch Analysis**
Elisabetta Rossi, Umberto Basso, Romina Celadin, Francesca Zilio, Salvatore Pucciarelli, Michele Aieta, Carmen Barile, Teodoro Sava, Giorgio Bonciarelli, Salvatore Tumolo, Cristina Ghiotto, Cristina Magro, Antonio Jirillo, Stefano Indraccolo, Alberto Amadori, and Rita Zamarchi

CANCER THERAPY: CLINICAL

5260 **Phase II Study of Daily Sunitinib in FDG-PET-Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation**
Laurie L. Carr, David A. Mankoff, Bernardo H. Goulart, Keith D. Eaton, Peter T. Capell, Elizabeth M. Kell, Julie E. Bauman, and Renato G. Martins

5269 **Lenalidomide in Nonmetastatic Biochemically Relapsed Prostate Cancer: Results of a Phase I/II Double-Blinded, Randomized Study**
Daniel Keizman, Marianna Zahurak, Victoria Sinibaldi, Michael Carducci, Samuel Denmeade, Charles Drake, Roberto Pili, Emmanuel S. Antonarakis, Susan Hudock, and Mario Eisenberger

5277 **A Phase I Study of a Tropism-Modified Conditionally Replicative Adenovirus for Recurrent Malignant Gynecologic Diseases**
Kristopher J. Kimball, Meredith A. Preuss, Mack N. Barnes, Minghui Wang, Gene P. Siegal, Wen Wan, Huichien Kuo, Souheil Saddekni, Cecil R. Stockard, William E. Grizzle, Raymond D. Harris, Rosemarie Aurigemma, David T. Curiel, and Ronald D. Alvarez

5288 **Farletuzumab, a Humanized Monoclonal Antibody against Folate Receptor α , in Epithelial Ovarian Cancer: a Phase I Study**
Jason A. Konner, Katherine M. Bell-McGuinn, Paul Sabbatini, Martee L. Hensley, William P. Tew, Neeta Pandit-Taskar, Nicholas Vander Els, Martin D. Phillips, Charles Schweizer, Susan C. Weil, Steven M. Larson, and Lloyd J. Old

- 5296 **Analysis of the Yield of Phase II Combination Therapy Trials in Medical Oncology**
Michael L. Maitland, Christine Hudoba, Kelly L. Snider, and Mark J. Ratain
- 5303 **Sequential Cytarabine and α -Particle Immunotherapy with Bismuth-213–Lintuzumab (HuM195) for Acute Myeloid Leukemia**
Todd L. Rosenblat, Michael R. McDevitt, Deborah A. Mulford, Neeta Pandit-Taskar, Chaitanya R. Divgi, Katherine S. Panageas, Mark L. Heaney, Suzanne Chanel, Alfred Morgenstern, George Sgouros, Steven M. Larson, David A. Scheinberg, and Joseph G. Jurcic
- 5312 **Safety and Clinical Effect of Subcutaneous Human Interleukin-21 in Patients with Metastatic Melanoma or Renal Cell Carcinoma: A Phase I Trial**
Henrik Schmidt, Janet Brown, Ulrik Mouritzen, Peter Selby, Kirsten Fode, Inge Marie Svane, Graham P. Cook, David Hal Mollerup, and Poul F. Geertsen
- 5320 **Overexpression of Tumor Vascular Endothelial Growth Factor A May Portend an Increased Likelihood of Progression in a Phase II Trial of Bevacizumab and Erlotinib in Resistant Ovarian Cancer**
Setsuko K. Chambers, Mary C. Clouser, Amanda F. Baker, Denise J. Roe, Haiyan Cui, Molly A. Brewer, Kenneth D. Hatch, Michael S. Gordon, Mike F. Janicek, Jeffrey D. Isaacs, Alan N. Gordon, Raymond B. Nagle, Heather M. Wright, Janice L. Cohen, and David S. Alberts

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

- 5329 **CD44 Expression Predicts Local Recurrence after Radiotherapy in Larynx Cancer**
Monique C. de Jong, Jimmy Pramana, Jacqueline E. van der Wal, Martin Lacko, Carine J. Peutz-Kootstra, Jos M. de Jong, Robert P. Takes, Johannes H. Kaanders, Bernard F. van der Laan, Jasper Wachters, Jeroen C. Jansen, Coen R. Rasch, Marie-Louise F. van Velthuysen, Reidar Grénman, Frank J. Hoebbers, Ed Schuurring, Michiel W. van den Brekel, and Adrian C. Begg
See commentary p. 5091

- 5339 **The IFNG (IFN- γ) Genotype Predicts Cytogenetic and Molecular Response to Imatinib Therapy in Chronic Myeloid Leukemia**
Dong Hwan (Dennis) Kim, Jee Hyun Kong, Ji Young Byeun, Chul Won Jung, Wei Xu, Xiangdong Liu, Suzanne Kamel-Reid, Yeo-Keyoung Kim, Hyeoung-Joon Kim, and Jeffrey H. Lipton
- 5351 **Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer**
Adel Tabchy, Vicente Valero, Tatiana Vidaurre, Ana Lluch, Henry Gomez, Miguel Martin, Yuan Qi, Luis Javier Barajas-Figueroa, Eduardo Souchon, Charles Coutant, Franco D. Doimi, Nuha K. Ibrahim, Yun Gong, Gabriel N. Hortobagyi, Kenneth R. Hess, W. Fraser Symmans, and Lajos Pusztai

OBITUARY

- 5362 **Merrill J. Egorin: In Memoriam (1948–2010)**
Jennifer R. Grandis

LETTERS TO THE EDITOR


- 5364 **Psychologic Intervention and Survival: Wishing Does Not Make It So – Letter**
Steven C. Palmer, Michael E. Stefanek, Brett D. Thombs, and James C. Coyne
- 5365 **Varying Opinions on the Authenticity of a Human Midgut Carcinoid Cell Line – Letter**
Lee M. Ellis, Shaija Samuel, and Eric Scekusi

CORRECTION

- 5367 **Correction: Targeting Rat Brainstem Glioma Using Human Neural Stem Cells and Human Mesenchymal Stem Cells**

ABOUT THE COVER

This image depicts the membrane β -catenin staining merged with DAPI in DU145 cells. The P-cadherin/ β -catenin signaling pathway not only stabilizes tumor and stromal cell-cell adhesions, it also represents a major regulatory mechanism for oncogenic signaling pathways. PF-03732010, a human monoclonal antibody against P-cadherin, functionally blocks the β -catenin signaling pathway and demonstrates antitumor and antimetastatic activity. Antagonizing P-cadherin with PF-03732010 represents a novel approach for anticancer therapy. For further details, please see the article by Zhang and colleagues on page 5177 of this issue.



Clinical Cancer Research

16 (21)

Clin Cancer Res 2010;16:5089-5367.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/16/21>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/16/21>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.